Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2026-01-15 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Myqorzo et Redemplo approuvés en Chine
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the regulatory approval of two drugs, Myqorzo and Redemplo, in China. It details the clinical background, the nature of the drugs, and the strategic importance of these approvals. As it is a general corporate announcement regarding product developments and regulatory milestones that does not fit into specific financial reporting categories like 10-K or ER, it is classified as a general regulatory announcement.
2026-01-15 French
Press Release: Myqorzo and Redemplo approved in China
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the regulatory approval of two new medicines (Myqorzo and Redemplo) in China. It provides details on the clinical studies, the nature of the diseases, and the company's strategic commitment. As it is a general corporate announcement regarding regulatory developments and product approvals that does not fit into specific financial reporting categories like 10-K or earnings releases, it is classified as a general regulatory filing.
2026-01-15 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2025
Notice of Dividend Amount Classification · 95% confidence The document is a regulatory disclosure required by French law (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) regarding the total number of voting rights and shares. This is a standard regulatory filing for French listed companies to update the market on share capital structure. It does not fit into specific categories like 'Share Issue' or 'Director's Dealing' as it is a periodic disclosure of total voting rights, making 'RNS' (Regulatory Filings) the most appropriate classification.
2026-01-14 French
Sanofi: Information concerning the total number of voting rights and shares - December 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal disclosure by Sanofi regarding the total number of voting rights and shares, issued in compliance with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation. This type of disclosure is a standard regulatory requirement for French listed companies to update the market on share capital and voting rights, which falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-01-14 English
Communiqué de presse : Teizeild de Sanofi approuvé dans l'UE pour les patients atteints de diabète de type 1 de stade 2
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the European Commission's approval of their drug 'Teizeild' for the treatment of type 1 diabetes. It details the clinical study results (TN-10), the regulatory approval status, and provides contact information for media and investor relations. As this is a standard corporate announcement regarding product development and regulatory milestones, it falls under the 'Regulatory Filings' category as a general corporate announcement.
2026-01-12 French
Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes
Regulatory Filings Classification · 95% confidence The document is a press release issued by Sanofi announcing the European Commission's approval of their drug 'Teizeild' for type 1 diabetes. It details the clinical study results (TN-10), the regulatory approval status, and provides contact information for media and investor relations. As it is a general corporate announcement regarding product development and regulatory milestones that does not fit into specific financial reporting categories like 10-K, IR, or ER, it is classified as a general regulatory filing.
2026-01-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.